Table 3 Capitalized expected costs and capitalized cost per approved drug
From: Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Drug Type | Phase | Mean phase length (days) | Capitalized expected clinical costs (in millions of 2013 USD) | Capitalized clinical cost per approved drug (in millions of 2013 USD) |
|---|---|---|---|---|
Non-orphan | 1 | 624 | $4.6 | $412.4 |
2 | 849 | $10.0 | ||
3 | 771 | $28.5 | ||
Total | $43.1 | |||
Orphan | 1 | 1198 | $8.8 | $291.3 |
2 | 1463 | $40.5 | ||
3 | 1506 | $46.6 | ||
Total | $95.9 | |||